NASDAQ:FTXH - Nasdaq - US33738R8372 - ETF - Currency: USD
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
A federal court blocked NIH's policy capping indirect cost rates on research grants, ruling it unlawful. The decision safeguards billions in funding and ongoing clinical trials.
The strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month. Here they are in detail.
Total earnings for 76.7% of the total healthcare market capitalization are up 11% on revenue growth of 7.2%. The growth rates seem unimpressive when compared with some of the other sectors.
Investors should focus on some strategies as to which sector should they take positions or which should be avoided if bipartisan government forms.
Total earnings for 83.5% of the total healthcare market capitalization are up 13.7% on revenue growth of 7.8%.